During the corresponding time, Springworks Therapeutics Inc recorded a revenue increase by 133.68 % year on year, sequentially revenue fell by -20.25 %. While revenue at the Springworks Therapeutics Inc 's corporate clients
Springworks Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is authorized to market OGSIVEO for the treatment of progressing desmoid tumors in adult patients requiring systemic therapy, and GOMEKLI for treating adult and pediatric patients aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete surgical resection in the United States. These products are primarily distributed through third-party specialty drug distributors and specialty pharmacies, with sales volume expected to be evenly distributed among these channels. OGSIVEO received FDA approval as the first and only therapy for desmoid tumors as of November 27, 2023. GOMEKLI is the first and only FDA-approved therapy for adult NF1-PN patients as of February 11, 2025, and is also approved for pediatric NF1-PN. AstraZeneca PLC’s Koselugo is the only other FDA-approved therapy for pediatric NF1-PN.
The company faces competition from major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and research organizations. Competitors developing treatments for desmoid tumors include Bayer Corporation, Eisai Co., LTD., Immunome, Inc., Iterion Therapeutics, Inc., MedPacto, Inc., and Parabilis Medicines, Inc. Off-label treatments for desmoid tumors include chemotherapeutic agents such as liposomal doxorubicin and vinblastine/methotrexate, non-steroidal anti-inflammatory drugs, anti-hormonal therapies, and tyrosine kinase inhibitors including sorafenib, imatinib, and pazopanib.
Competitors developing therapies for NF1-PN include Array BioPharma Inc. (a subsidiary of Pfizer), Chia Tai Tianqing Pharmaceutical Group Co., LTD, Healx Ltd., Infixion Bioscience, Inc., NFlection Therapeutics, Inc., Novartis International AG, Pasithea Therapeutics Corp., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Shanghai Kechow Pharma, Inc. Several generic therapies are also used off-label for NF1-PN.
European Commission Grants Conditional Approval of EZMEKLY (mirdametinib) for Treatment of Neurofibromatosis Type 1-Associated Peripheral Nerve Sheath Tumors (NF1-PN)In a groundbreaking development for patients suffering from Neurofibromatosis Type 1 (NF1), the European Commission has granted conditional marketing authorization for EZMEKLY (mirdametinib). This marks a significant milestone as EZMEKLY becomes the first and only therapy authorized in the European Union for the treatment of both adult and pediatric patients, including those as young as two years old, suffering from NF1-associated peripheral nerve sheath tumors (NF1-PN). Understanding NF1-PN: A Rare Genetic DisorderNeurofibromatosis Type 1 is a...
In a recent announcement, SpringWorks Therapeutics revealed that the European Medicines Agency (EMA) has validated the marketing authorization application for Nirogacestat, a potential breakthrough treatment for adults with Desmoid Tumors. This milestone comes after the Phase 3 DeFi trial showcased significant improvements in various aspects of patients lives compared to a placebo.The Phase 3 DeFi trial formed the basis of the marketing authorization application, demonstrating that Nirogacestat not only enhanced progression-free survival but also significantly improved the response rate when compared to the placebo. Moreover, it achieved rapid and sustained improvements in symptom burden, including pain ma...
Springworks Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is authorized to market OGSIVEO for the treatment of progressing desmoid tumors in adult patients requiring systemic therapy, and GOMEKLI for treating adult and pediatric patients aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete surgical resection in the United States. These products are primarily distributed through third-party specialty drug distributors and specialty pharmacies, with sales volume expected to be evenly distributed among these channels. OGSIVEO received FDA approval as the first and only therapy for desmoid tumors as of November 27, 2023. GOMEKLI is the first and only FDA-approved therapy for adult NF1-PN patients as of February 11, 2025, and is also approved for pediatric NF1-PN. AstraZeneca PLC’s Koselugo is the only other FDA-approved therapy for pediatric NF1-PN.
The company faces competition from major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and research organizations. Competitors developing treatments for desmoid tumors include Bayer Corporation, Eisai Co., LTD., Immunome, Inc., Iterion Therapeutics, Inc., MedPacto, Inc., and Parabilis Medicines, Inc. Off-label treatments for desmoid tumors include chemotherapeutic agents such as liposomal doxorubicin and vinblastine/methotrexate, non-steroidal anti-inflammatory drugs, anti-hormonal therapies, and tyrosine kinase inhibitors including sorafenib, imatinib, and pazopanib.
Competitors developing therapies for NF1-PN include Array BioPharma Inc. (a subsidiary of Pfizer), Chia Tai Tianqing Pharmaceutical Group Co., LTD, Healx Ltd., Infixion Bioscience, Inc., NFlection Therapeutics, Inc., Novartis International AG, Pasithea Therapeutics Corp., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Shanghai Kechow Pharma, Inc. Several generic therapies are also used off-label for NF1-PN.
Sources:
Springworks Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Springworks Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Springworks Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
